Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for ...

Health Canada has approved an RSV vaccine for adults over the age of 60 — something many doctors were "happy" to learn. The agency approved GSK’s Arexvy vaccine for the prevention of RSV ...

GSK’s Arexvy is already approved in the US for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at ...

On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older.

Analysts at TD Cowen had expected third quarter sales of Arexvy, the RSV vaccine, of just £300 million ($364 million). On Tuesday, Pfizer (ticker: PFE) reported third-quarter sales of its RSV ...

Arexvy, made by GSK, is indicated for adults aged 60 years and older, the agency announced Wednesday. Like flu, RSV is highly contagious and causes seasonal outbreaks.

In the US, one study suggested Abrysvo and Arexvy were associated with nine and seven excess Guillain-Barre syndrome cases per million vaccine doses administered, respectively.

GSK PLC GSK -2.45% raised its guidance after third-quarter net profit rose mainly due to the U.S. launch of its Arexvy vaccine, although it missed analysts’ forecasts. The British pharmaceutical ...